Project Grant R01FD006919

This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $162,501.00 to The Trustees of the University of Pennsylvania to conduct a pilot study on veterinary antifungal use and resistance in support of the FDA's Vet-LIRN antimicrobial stewardship efforts. The key objectives are to: 1) Develop and implement a survey of companion animal veterinarians to assess their knowledge, attitudes, and practices regarding antifungal...

This $4,753,460 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized Phase 2 clinical trial evaluating the PI3KD inhibitor roginolisib in combination with venetoclax and rituximab for the treatment of relapsed chronic lymphocytic leukemia (CLL) patients. The study will be conducted by the Dana-Farber Cancer Institute, Inc. (DFCI), a prestigious non-profit cancer research center in Boston, Massachusetts....

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop and test optimized formulations of a combination drug therapy for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The $318,488 award will fund feasibility studies in dogs and mice to identify the most desirable pharmacokinetic parameters and...

The federal Project Grant award R01CA298377, funded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program), is supporting research to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award, granted to Northwestern University, has two key aims: Determining whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary trial....

This federal Project Grant award, provided by the National Institute on Aging under the Aging Research program (CFDA 93.866), funds the "Test of Rapamycin in Aging Dogs" (TRIAD) clinical trial. The TRIAD study aims to determine whether once-weekly rapamycin treatment can increase lifespan and improve healthspan in 580 companion dogs. The $2,015,762 award, with a period of performance from December 1, 2024 to November 30, 2029, supports the randomized, double-blind, placebo-controlled...

This $186,254 Project Grant award from the Fogarty International Center (CFDA 93.989 - International Research and Research Training) aims to investigate the potential of synchronized dog vaccination campaigns as an approach to improving dog vaccination coverage and health outcomes in Africa. The research will be conducted by the Ifakara Health Institute, a non-profit research organization based in Tanzania. The key objectives are to: 1) Determine if synchronized dog vaccination campaigns can...

This Project Grant award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $882,247 to the University of Pittsburgh to conduct a Phase 2 clinical trial evaluating the use of interferon-gamma (IFN-γ) and donor lymphocyte infusion (DLI) for treating relapsed myeloid malignancies in patients who have undergone allogeneic stem cell transplantation. The study aims to assess the efficacy of the IFN-γ/DLI treatment regimen compared to synthetic control cohorts, with...

The National Cancer Institute (NCI) awarded a $667,533 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, for the project "Targeting Lymphoma: A Multimodal Approach Using Radiation, CAR-T Therapy, and Gut Microbiome Modulation." The project aims to optimize the combination of radiation therapy (RT), chimeric antigen receptor T-cell...

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded Lumen Bioscience, Inc. a $16,288,194 project grant to conduct a Phase 2/3 clinical trial evaluating LMN-201, an anti-infective therapeutic for the treatment and prevention of Clostridioides difficile (C. difficile) infection. The randomized, double-blind, placebo-controlled study will take place in Seattle, WA and is expected to be completed by September 14, 2027. Lumen Bioscience, a...

This Project Grant award for $399,187 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support Virginia Commonwealth University's research to develop novel genetically engineered mouse models to study the development of marginal zone lymphomas (MZL). The research aims to 1) investigate the impact of activation of the PI3K/AKT/mTOR pathway on MZL development, and 2) determine optimal drug combinations for targeting this pathway in MZL. This work seeks to establish...